

# Goldman Sachs Analysts: Biggest Risks to COVID Vaccination Targets in US, Europe Are Confidence-Related

By [Zero Hedge](#)

Global Research, December 16, 2020  
[Zero Hedge](#)

Region: [Europe, USA](#)


Theme: [Science and Medicine](#)

*Goldman Sachs analysts have updated and expanded [their popular research](#) detailing the outlook for vaccine rollout in both the US and internationally. As the FDA prepares to grant the virtually inevitable approval of the Moderna mRNA COVID vaccine later this week, **the investment bank has expanded its monthly forecasting vaccination model by including the major emerging markets and the ten leading global vaccine candidates.***

Looking further down the road, more analysts have been discussing the prospect that we might actually see a glut of vaccine doses sooner than many had expected (at least, in the wealthy countries that have managed to strike distribution deals with the vaccinemakers, and aren't relying on Bill Gates and the WHO to bail them out).

Should the "top 10" developers achieve their production targets (note: [Pfizer has already cut its 2020 year-end deliver target in the US by 50%](#)) enough doses could be delivered to vaccinate 85% of the world's population by the end of next year.

Speaking of the Pfizer target cuts, one of the most important differences in Goldman's latest update is that the bank and its analysts have tweaked their models to account for the stage of a company's trial, **as well as - and this is important - the company's experience in mass production.**




Source: Goldman Sachs Global Investment Research

These “tweaks” are an attempt to “account for potential production misses,” according to the authors of the research.

Additionally, the bank’s analysts have taken the liberty of “allocating” all the non-committed doses to account for likely future contracts between developers and nations (presumably these are based on media reports and other chatter/speculation).

Exhibit 2: Currently Contracted Vaccine Supply Is Much Larger for DMs than for EMs




Source: Goldman Sachs Global Investment Research

But assuming all the vaccinemakers meet their various development targets (which, if the past is any guide, probably won’t happen) Goldman believes it’s “realistic” to expect 50% of the developed world population to be vaccinated by April, including for the US and the UK, May for Canada, June for the EU and Australia, and July for Japan.

Most larger EM countries can expect to meet the 50% threshold sometime during the second half of 2021. While Goldman expects its DM projections to be more “resilient”, EM production targets, due to various vagaries surrounding their capacity for storage and

distribution, are more “vulnerable” to being thwarted.


**Exhibit 7: We Expect Most DMs to Vaccinate 50% of Their Populations by Late Q2 and EMs to Follow by Late 2021**



Source: Goldman Sachs Global Investment Research

Whatever ultimately happens, Goldman expects that no matter what, supplies in the emerging world will always trail the developing world, and - more importantly - **the developing world won't see its vaccination rate really begin to rise until after the developed world has ensured its citizens get all the first helpings.**


**Exhibit 5: Low-Income EMs Appear Less Well Positioned for Rapid Distribution than DMs**



For Australia, Brazil, Mexico and Russia, we predict over 65 2019 flu vaccination rates using 2003 population vaccination rates and 2019 GDP per capita. For India and China, we assume that the over 65 flu vaccination rate is 5%. Covid testing and tracing is calculated using indicators from the Oxford Government Response Tracker. For both the testing and tracing indicators, we calculate the mean score between April and June (February and April for China due to an earlier start of the pandemic). We take the average of these two scores for the combined Covid testing & tracing variable.

Source: OECD, van Essen et al. (2003), Sustainable Development Solutions Network, World Bank, Oxford University, Goldman Sachs Global Investment Research

**Exhibit 6: Distribution and Supply Constraints Are Expected to Bind More in EMs Such as Mexico**




Source: Goldman Sachs Global Investment Research

In one of the more interesting charts breaking down obstacles to official vaccination targets in various DM and EM countries, **Goldman points out, ever so diplomatically, that “demand issues” are the biggest issue in the US, while “supply issues” are the biggest problem in EM.**

And by “demand issue”, the bank means that not enough people will voluntarily go get vaccinated, for whatever reason – whether it’s a lack of “confidence” in safety and efficacy, or perhaps a financial reason (even though lawmakers and the president have repeatedly promised that all that would be ‘free to all’).

**Exhibit 8: Most DMs Are Vulnerable to Demand Setbacks While EMs Are More Vulnerable to Distribution Delays**




Source: Goldman Sachs Global Investment Research

Finally, the bank’s analysts apparently felt obliged to highlight one risk that could seriously delay the global rollout, both in the developed world, but – more seriously – in the developing world: and that would be if the three leading adenovirus-vector vaccines – AstraZeneca, Johnson & Johnson, CanSino – don’t succeed in meeting their efficacy targets.

After all, AZ did everything it could to mask the surprisingly low headline efficacy number (under 70%) from its Phase 3 trials, which were plagued by halts and suspicions about serious side effects in a small number of subjects (though so far there has been nothing to affirm that the vaccine was directly involved). And while Russia has boasted about high efficacy figures for “Sputnik 5”, the adenovirus vaccine developed by the Gamaleya institute, we imagine most American bankers are taking those numbers with a grain of salt.

Still, Goldman says its outlook for the vaccine rollout undergirds its call for a strong rebound in economic growth next year. And they're not alone: according to the latest BofA fund managers' survey, virtually all the professional money managers surveyed expect the positive impact from the vaccines to be felt next year, with more than 40% believing that a "positive impact" will begin during Q1.

**Exhibit 10: When do you think a COVID-19 vaccine will start positively impacting economic activity?**



When asked when they think the COVID-19 vaccine starts positively impacting the economy, 42% of investors replied Q2'21, 28% said Q1'21, 19% said Q3'21. FMS investors on average expect the vaccine to positively impact the economy by May 2021.

Source: BofA Global Fund Manager Survey

The question is: [should they feel the same way about AstraZeneca's results?](#)

\*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is by Viacheslav Lopatin (Credit: scaliger - stock.adobe.com)

The original source of this article is [Zero Hedge](#)

Copyright © [Zero Hedge](#), [Zero Hedge](#), 2020

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Zero Hedge](#)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)

[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)